Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 3/20 | 0.44 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9245663 | 0.92 | HSD17B1 (0.44) | HSD17B1PBRM1CASP1CASP7HSD17B10 | |
| SCHEMBL30042961 | 0.92 | HSD17B1 (0.44) | HSD17B1PBRM1CASP1CASP7HSD17B10 | |
| SCHEMBL16858594 | 0.89 | MAPK1 (0.49) | HSD17B1MEN1MAPK1KMT2ANPSR1 | |
| SCHEMBL31591224 | 0.83 | PBRM1 (0.47) | HSD17B1PBRM1CASP1CASP7HSD17B10 | |
| SCHEMBL30081454 | 0.83 | HSD17B1 (0.49) | HSD17B1PBRM1CASP1CASP7HSD17B10 | |
| SCHEMBL23051659 | 0.83 | PBRM1 (0.47) | HSD17B1PBRM1CASP1CASP7HSD17B10 | |
| SCHEMBL782926 | 0.83 | HSD17B1 (0.49) | HSD17B1PBRM1CASP1CASP7HSD17B10 | |
| SCHEMBL14059190 | 0.81 | MAPK1 (0.44) | HSD17B1MEN1MAPK1KMT2ANPSR1 | |
| SCHEMBL21155472 | 0.81 | MAPK1 (0.49) | HSD17B1MEN1MAPK1KMT2ANPSR1 | |
| SCHEMBL31511769 | 0.77 | HSD17B1 (0.43) | HSD17B1PBRM1CASP1CASP7HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3950676-B1 | PREPARATION METHOD FOR AMIDE COMPOUNDS AND APPLICATION THEREOF IN FIELD OF MEDICINE | SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO LTD (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-12595267-B2 | Preparation method for amide compound and application thereof in field of medicine | SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD. (CN) | 2026-04-07 | — | — | US | disclosed |
| US-12522602-B2 | Derivatives having 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2026-01-13 | — | — | US | disclosed |
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4389744-B1 | DERIVATIVES HAVING 2,3-DIHYDRO-1H-INDENE OR 2,3-DIHYDROBENZOFURAN MOIETY OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORP (KR) | 2025-12-03 | — | — | EP | disclosed |
| US-20250353817-A1 | INTERLUKIN-17A INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4598933-A1 | PHOSPHORAMIDATE COMPOUNDS AND USES THEREOF | Allorion Therapeutics Inc (US) | 2025-08-13 | — | — | EP | disclosed |
| CN-120081791-A | Heteroaryl compounds, process for their preparation and their use in medicine | 江苏恒瑞医药股份有限公司 | 2025-06-03 | — | — | CN | disclosed |
| US-20250154107-A1 | 3,4-Dihydroisoquinolin-1(2H)-Ones Derivatives as STING Antagonists and the Use Thereof | BEIGENE SWITZERLAND GMBH (CH) | 2025-05-15 | — | — | US | disclosed |
| US-20150284381-A1 | AMINO-PYRIDINE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK SHARP & DOHME CORP. | 2015-10-08 | — | — | US | disclosed |
| US-20150284381-A1 | AMINO-PYRIDINE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK SHARP & DOHME CORP. | 2015-10-08 | — | — | US | disclosed |
| EP-2916836-A1 | AMINO-PYRIDINE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-09-16 | — | — | EP | disclosed |
| EP-1740579-B1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2015-08-19 | — | — | EP | disclosed |
| WO-2015084692-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-06-11 | — | — | WO | disclosed |
| WO-2014074422-A1 | AMINO-PYRIDINE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-05-15 | — | — | WO | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| EP-1740579-A1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | Abbott Laboratories (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005095387-A1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT1, PRMT5, PRMT6 | HSD17B1 2858/4885PBRM1 70/4885CASP1 3686/4885 |
| US-20250353817-A1 | INTERLUKIN-17A INHIBITORS AND USES THEREOF | IL17A, IL15, IL23R | HSD17B1 64/4885PBRM1 3781/4885CASP1 117/4885 |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT9 | HSD17B1 3229/4885PBRM1 240/4885CASP1 3087/4885 |
| US-12595267-B2 | Preparation method for amide compound and application thereof in field of medicine | EZH2, BMI1, EHMT1 | HSD17B1 1341/4885PBRM1 51/4885CASP1 4086/4885 |
| US-20150284381-A1 | AMINO-PYRIDINE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS | SYK, BTK, LCK | HSD17B1 4653/4885PBRM1 1319/4885CASP1 1330/4885 |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | HSD17B1 3698/4885PBRM1 988/4885CASP1 2298/4885 |
| US-20250154107-A1 | 3,4-Dihydroisoquinolin-1(2H)-Ones Derivatives as STING Antagonists and the Use Thereof | STING1, IRF3, MAVS | HSD17B1 4065/4885PBRM1 3088/4885CASP1 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.